论文部分内容阅读
目的研究食管癌晚期老龄患者应用替吉奥辅以调强放疗的临床疗效。方法 46例食管癌晚期老龄患者,随机分为研究组和对照组,每组23例。对照组患者单纯实施调强适形放疗,研究组在对照组治疗基础上应用替吉奥治疗。对比两组的近期疗效及不良反应发生情况。结果研究组总有效率为82.61%,显著高于常规组的52.17%,差异有统计学意义(P<0.05)。两组患者均发生了不良反应,但均顺利完成治疗。两组患者消化道反应、放射性食管炎、骨髓抑制及转氨酶异常发生情况比较差异无统计学意义(P>0.05)。结论食管癌晚期老龄患者应用替吉奥辅以调强放疗其临床效果显著,不会显著增加毒副反应,老年患者可耐受并顺利完成治疗。
Objective To study the clinical efficacy of tegaserod in the treatment of advanced esophageal cancer with intensity-modulated radiotherapy. Methods Forty-six patients with advanced esophageal cancer were randomly divided into study group and control group, with 23 cases in each group. Patients in the control group were treated with intensity-modulated conformal radiotherapy alone, and the study group was treated with treatment of teglitazone on the basis of the control group. The two groups compared the short-term efficacy and adverse reactions. Results The total effective rate was 82.61% in the study group, which was significantly higher than 52.17% in the conventional group (P <0.05). Adverse reactions occurred in both groups, but the treatment was successfully completed. The two groups of patients with gastrointestinal reactions, radiation esophagitis, myelosuppression and abnormalities of transaminases showed no significant difference (P> 0.05). Conclusion The application of TIGO supplemented with intensity-modulated radiotherapy in elderly patients with advanced esophageal cancer has significant clinical effect, does not significantly increase the side effects, and elderly patients can tolerate and successfully complete the treatment.